文献速递头颈部肿瘤放疗放疗物理与技术

头颈癌幸存者放射性颈部纤维化的正常组织并发症概率模型:基于患者报告结局的分析

Normal tissue complication probability modeling of radiation-induced neck fibrosis in head and neck Cancer survivors: a patient-reported outcome-based analysis.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-07-31

本研究在95例根治性头颈放疗后缓解患者中,采用改编自硬皮病研究的22条SSPRO量表评估颈部纤维化相关生活质量损害,并行LKB NTCP建模。结果显示SSPRO与标准生活质量量表中度至强相关,非手术患者皮肤、胸锁乳突肌和皮下组织剂量与SSPRO评分恶化正相关,手术患者未见稳健剂量效应。

要点

  • SSPRO可捕捉标准头颈生活质量量表未完全反映的颈部纤维化相关损害。
  • 非手术患者中,皮肤、胸锁乳突肌和皮下组织剂量可预测纤维化相关PRO恶化。
  • 探索性再计划分析提示候选约束可能技术可行,但需前瞻性验证。

核心结论

  • SSPRO可捕捉标准头颈生活质量量表未完全反映的颈部纤维化相关生活质量损害。
  • 基于患者报告结局的NTCP建模提示,非手术患者中皮肤、胸锁乳突肌和皮下组织剂量可预测纤维化相关PRO恶化。
  • 探索性再计划分析提示候选约束可能技术可行,需前瞻性验证后再临床实施。

研究设计与样本

  • IRB批准的前瞻性试验中,纳入95例根治性头颈放疗后缓解患者。
  • 患者完成EORTC QLQ-C30、QLQ-H&N43及22条SSPRO量表。
  • 回顾性勾画颈部OAR(皮肤、皮下组织、胸锁乳突肌),采用LKB NTCP建模分析剂量体积指标。

主要发现

  • 95例患者均完成SSPRO、QLQ-C30和QLQ-H&N43。
  • SSPRO与既有生活质量量表呈中度至强相关。
  • 按预设阈值(轻度0-20、中度21-40、重度≥41),纤维化相关症状负担为轻度64.4%、中度20.0%、重度15.6%。
  • 非手术患者中,皮肤、胸锁乳突肌和皮下组织的平均剂量及部分V_x指标越高,SSPRO评分越差。
  • 手术患者中未见稳健的剂量-反应关系。

关键数值与推荐

  • SSPRO总分预设分级阈值:轻度0-20、中度21-40、重度≥41。
  • 非手术患者中,皮肤、胸锁乳突肌和皮下组织较高平均剂量及部分V_x指标与SSPRO评分恶化正相关。
  • 手术患者中未观察到稳健的剂量-反应关系。

临床怎么用

  • 可考虑使用SSPRO评估头颈放疗后颈部纤维化相关功能和生活质量损害。
  • 非手术患者放疗计划中应关注皮肤、胸锁乳突肌和皮下组织的剂量体积参数。
  • 候选剂量约束需前瞻性验证后方可用于临床。

局限性

  • 探索性再计划分析提示候选约束可能技术可行,但需前瞻性验证后方可临床实施。
  • 手术患者中未见稳健剂量-反应关系,可能限制NTCP模型在该人群的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Skin and soft tissue fibrosis of the neck is a common late toxicity after head and neck radiotherapy (Muehlebach et al., 2025; Ramia et al., 2022; Strojan et al., 2017 [1], [2], [3]), yet no dedicated patient-reported outcome (PRO) instrument exists to capture its specific functional and quality-of-life (QOL) impact. Renslo et al. (2024), Shaw et al. (2016) [4], [5], [6] This study evaluates a fibrosis-directed PRO adapted from scleroderma research and explores dosimetric correlates and normal tissue complication probability (NTCP) relationships for neck fibrosis. [7]. MATERIALS AND METHODS: In an IRB-approved prospective trial, 95 patients in remission after curative-intent head and neck radiotherapy completed the EORTC QLQ-C30, QLQ-H&N43, and the 22-item Scleroderma Skin Patient-Reported Outcome (SSPRO) instrument. [7], [8], [9] Neck organs at risk (OARs) constituting skin, subcutaneous tissue, and sternocleidomastoid (SCM) muscle were retrospectively contoured; dose-volume metrics are analyzed using Lyman-Kutcher-Burman (LKB) NTCP modeling. RESULTS: All 95 patients completed SSPRO, QLQ-C30, and QLQ-H&N43. Correlation analyses showed moderate-to-strong associations between SSPRO and established QOL instruments. SSPRO total scores categorized using pre-specified thresholds (mild 0-20, moderate 21-40, severe ≥41) showed 64.4% mild, 20.0% moderate, and 15.6% severe fibrosis-related symptom burden. In non-surgical patients, higher mean dose and selected V_x metrics to skin, SCM, and subcutaneous tissue were positively associated with worsening SSPRO scores, whereas no robust dose-response was seen in surgically treated patients. CONCLUSIONS: SSPRO captures neck fibrosis-related QOL impairment that is incompletely reflected by standard head and neck QOL instruments. PRO-anchored NTCP modeling suggests that dose to skin, SCM, and subcutaneous tissue predicts fibrosis-related PRO deterioration in non-surgical patients. Eisbruch et al. (1999, 2004), Murdoch-Kinch et al. (2008), Nutting et al. (2011) [10], [11], [12], [13], [14] Exploratory replanning analyses suggest these candidate constraints may be technically achievable and warrant prospective validation before clinical implementation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Azzam GA, Cerbon D, Huang L, et al. Normal tissue complication probability modeling of radiation-induced neck fibrosis in head and neck Cancer survivors: a patient-reported outcome-based analysis. Clin Transl Radiat Oncol. 2026. PMID: 42568945. doi:10.1016/j.ctro.2026.101247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。